Table 1

Data from the Marseille cohort
All patients Patients with normal platelets count Patients with thrombocytopenia p
Number of patients 43 6 37
Number of episodes 56 10 46
Number of relapsing patients 10 3 7 0.88
Sex (%male) 40% 17% 43% 0.40
Age (years) 45 [25–64] 40 [32–50] 44 [23–66] 0.78
Biopsy proven TMA 10 (23%) 3 (50%) 7 (19%) 0.38
Etiology identification 24 (56%) 3 (50%) 21 (57%)
  Identified mutation 6 2 4
  Anti-factor H Autoantibody 1 1
  Toxic 5 1 4
  Cancer associated 2 2
  Graft associated 2 1
  Autoimmune disease 3 3
  Shiga like toxin 4 4
  Post infectious disease 2 2
Potential explanation 10 (23%) 2 (33%) 8 (22.5%)
  Familial form 2 2
  Recurrent form 4 2 2
  Associated with low C3 4 4
Idiopathic 9 (21%) 1 (17%) 8 (22.5%)
Pregnancy associated HUS 3 (11,5%) 2 (40%) 1 (5%) 0.151
Platelets (G/L)* 66 [55–108] 234 [183–265] 53 [27–88] < 0.001
Hb (g/dl) 7.6 [7.1-8.9] 8 [7.2-9.8] 7.7 [7.1-8.8] 0.38
LDH* (UI/L) 1012 [607–202] 612 [400–705] 1074 [659–2192] 0.012
Haptoglobin 0 [0–0] 0 [0–0,28] 0 [0–0] 0.064
Schizocytes %* 2.2 [1.5-3.8] 0.8 [0–2] 3 [1.5-4.4] < 0.001
Creatinine (mg/dl) 3.4 [2.4-5.5] 2.5 [1.4-5.3] 3.5 [2.5-5.6] 0.76
Proteinuria (g/24h) 2.2 [1.1 – 3.6] 1.5 [0.8 – 2.3] 2.32 [1.2 – 4] 0.15
HD at the diagnosis 12 (21%) 2 (20%) 10 (22%) 0.68
HD during the episode 34 (61%) 5 (50%) 29 (63%) 0,6
Death (%) 1 (2%) 1 (17%) 0 (0%) 0,6
Plasmatherapy
  Number of episodes treated 52 (93%) 8 (80%) 44 (96%) 0.88
  Number of plasmatherapy sessions 15 [12–18] 15 [6–16.5] 14 [12–20]

For Numeric value, data are express in Median value [25%-75%], for categories, data are express in number of observation (%). Test used, Mann Whitney test (quantitative data) and Fisher's test for proportion and rate. Note, Conversion factors for units, serum creatinine in mg/dL to mol/L, ×88.4; serum urea nitrogen in mg/dL to mmol/L.

Sallée et al.

Sallée et al. BMC Nephrology 2013 14:3   doi:10.1186/1471-2369-14-3

Open Data